Adorni F - Search Results

1

Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population.

Rusconi S, Giacomet V, Mameli C, Viganò A, Viganò O, Adorni F, Galli M, Zuccotti GV. Rusconi S, et al. Among authors: adorni f. BMC Infect Dis. 2012 Aug 6;12:179. doi: 10.1186/1471-2334-12-179. BMC Infect Dis. 2012. PMID: 22866946 Free PMC article.

2

Does GSS still maintain relevance on HAART outcome after the introduction of newest active antiretroviral drugs? 48 weeks results.

Ortu M, Vitiello P, Adorni F, Rossotti R, Di Vincenzo P, Vigano O, Galli M, Rusconi S. Ortu M, et al. Among authors: adorni f. Curr HIV Res. 2011 Dec 1;9(8):625-9. doi: 10.2174/157016211798998790. Curr HIV Res. 2011. PMID: 22211659 Free article.

3

Thrombotic microangiopathy in patients with acquired immunodeficiency syndrome before and during the era of introduction of highly active antiretroviral therapy.

Gervasoni C, Ridolfo AL, Vaccarezza M, Parravicini C, Vago L, Adorni F, Cappelletti A, d'Arminio Monforte A, Galli M. Gervasoni C, et al. Among authors: adorni f. Clin Infect Dis. 2002 Dec 15;35(12):1534-40. doi: 10.1086/344778. Epub 2002 Dec 2. Clin Infect Dis. 2002. PMID: 12471574

4

Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.

Chiesa E, Bini T, Adorni F, Capetti A, Rizzardini G, Faggion I, Mussini C, Sollima S, Melzi S, Bongiovanni M, Tordato F, Cicconi P, Castelnuovo B, Rusconi S, d'Arminio Monforte A. Chiesa E, et al. Among authors: adorni f. Antivir Ther. 2003 Feb;8(1):27-35. Antivir Ther. 2003. PMID: 12713061

5

Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutations.

Bongiovanni M, Bini T, Adorni F, Meraviglia P, Capetti A, Tordato F, Cicconi P, Chiesa E, Cordier L, Cargnel A, Landonio S, Rusconi S, d'Arminio Monforte A. Bongiovanni M, et al. Among authors: adorni f. Antivir Ther. 2003 Jun;8(3):209-14. Antivir Ther. 2003. PMID: 12924537 Clinical Trial.

6

Vpr and HIV-1 disease progression: R77Q mutation is associated with long-term control of HIV-1 infection in different groups of patients.

Mologni D, Citterio P, Menzaghi B, Zanone Poma B, Riva C, Broggini V, Sinicco A, Milazzo L, Adorni F, Rusconi S, Galli M, Riva A; rHoPeS Group. Mologni D, et al. Among authors: adorni f. AIDS. 2006 Feb 28;20(4):567-74. doi: 10.1097/01.aids.0000210611.60459.0e. AIDS. 2006. PMID: 16470121

7

Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers.

Ferraris L, Viganò O, Peri A, Tarkowski M, Milani G, Bonora S, Adorni F, Gervasoni C, Clementi E, Di Perri G, Galli M, Riva A. Ferraris L, et al. Among authors: adorni f. J Antimicrob Chemother. 2012 Sep;67(9):2236-42. doi: 10.1093/jac/dks175. Epub 2012 Jun 2. J Antimicrob Chemother. 2012. PMID: 22661571 Clinical Trial.

8

Changes in the incidence of severe thrombocytopenia and its predisposing conditions in HIV-infected patients since the introduction of highly active antiretroviral therapy.

Franzetti M, Adorni F, Oreni L, Van Den Bogaart L, Resnati C, Milazzo L, Antinori S, Galli M, Ridolfo AL. Franzetti M, et al. Among authors: adorni f. J Acquir Immune Defic Syndr. 2014 Dec 15;67(5):493-8. doi: 10.1097/QAI.0000000000000347. J Acquir Immune Defic Syndr. 2014. PMID: 25230291

9

96-week results of a dual therapy with darunavir/ritonavir plus rilpivirine once a day vs triple therapy in patients with suppressed viraemia: virological success and non-HIV related morbidity evaluation.

Di Cristo V, Adorni F, Maserati R, Annovazzi Lodi M, Bruno G, Maggi P, Volpe A, Vitiello P, Abeli C, Bonora S, Ferrara M, Cossu MV, Oreni ML, Colella E, Rusconi S. Di Cristo V, et al. Among authors: adorni f. HIV Res Clin Pract. 2020 Feb;21(1):34-43. doi: 10.1080/25787489.2020.1734752. Epub 2020 Mar 4. HIV Res Clin Pract. 2020. PMID: 32129161 Free article. Clinical Trial.

10

Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection.

d'Arminio Monforte A, Testa L, Adorni F, Chiesa E, Bini T, Moscatelli GC, Abeli C, Rusconi S, Sollima S, Balotta C, Musicco M, Galli M, Moroni M. d'Arminio Monforte A, et al. Among authors: adorni f. AIDS. 1998 Sep 10;12(13):1631-7. doi: 10.1097/00002030-199813000-00010. AIDS. 1998. PMID: 9764782 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

96 results

Search Page

Filters